Author: Chin-Lin Chen, Ph.D / Data Scientist at Vizuro Key Takeaway Drug discovery has entered the era of big data. Every year, thousands of disease and normal samples are profiled — yet one critical bottleneck remains: identifying clinically meaningful target–marker gene pairs for new drug development . The core value of Apotek Path is for this purpose: Identify disease-relevant targets → Causal modeling reveals mechanistic gene interactions tailored to your disease contex

The future of Physical AI isn't just about better technology—it's about smarter SDG implementation. Organizations that understand how to match SDG strategies with their specific Physical AI needs will gain significant competitive advantages.

Why causal AI is becoming pharma’s next strategic differentiator — from target validation to clinical trials and real-world evidence. Visualizing the Ladder of Causation in Pharma: from seeing correlations, to doing interventions, to imagining counterfactuals — the foundation of causal AI in drug discovery. Introduction: The Limits of Correlation in Drug Discovery Drug discovery today generates unprecedented volumes of data. Omics, imaging, electronic health records, and real

How Corvus's synthetic data generation platform addresses the critical challenge of matching model capabilities with data requirements...

Ad platform reports from Google, Meta, and others usually over-credit the last click and don’t reveal the true drivers of ROI....